In addition, inhibition of HIF-1α and HIF-2α activity interferes with tumor growth and vascularization as well as reprogramming of the tumor immune microenvironment to promote anti-tumor immunity and improve the response to anti-programmed cell death protein 1 therapy (86, 245–248). This evidence concerns the gene PDCD1 and neoplasm.